Clinical Trials · NCT06588283
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 281
- Start date
- Sep 2024
- Locations
- 72 sites, United States, Puerto Rico
- Primary endpoint
- Percentage of Participants Who Simultaneously Achieved Psoriasis Area and Severity Index (PASI) 100 and At Least 10% Weight Reduction